Ascendis Pharma Join Forces with Novo Nordisk to Develop and Commercialize TransCon Tech-based Products in Metabolic and Cardiovascular Indications
Shots:
- Novo Nordisk has secured an exclusive global license to use Ascendis’ TransCon tech to develop its metabolic disease programs, with rights to expand into other areas & a product-by-product exclusive license in cardiovascular diseases. The lead will be a QM GLP-1 receptor agonist for obesity & T2D
- Ascendis will receive $285M as upfront, development & regulatory milestones for the lead, plus sales milestones & tiered royalties; additional products may yield up to $77.5M each in development & regulatory milestones, along with sales milestones & royalties. Closing is expected by YE’24, pending regulatory approvals
- Ascendis will lead early development, with Novo Nordisk covering the costs & handling clinical development, manufacturing & commercialization
Ref: Ascendis | Image: Novo Nordisk & Ascendis
Related News:- Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
